Genocea Biosciences, Inc. (NASDAQ:GNCA) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.54) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.50) by $0.04, Briefing.com reports.
Genocea Biosciences (GNCA) traded down 14.55% on Wednesday, reaching $4.11. The company’s stock had a trading volume of 1,254,098 shares. Genocea Biosciences has a 52-week low of $3.28 and a 52-week high of $7.29. The firm’s market cap is $117.14 million. The stock’s 50 day moving average price is $5.30 and its 200 day moving average price is $5.50.
In related news, CFO Jonathan Poole sold 45,000 shares of the firm’s stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $6.00, for a total transaction of $270,000.00. Following the transaction, the chief financial officer now directly owns 84,247 shares in the company, valued at approximately $505,482. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 6.70% of the stock is owned by company insiders.
A number of research firms recently commented on GNCA. ValuEngine downgraded Genocea Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Cowen and Company reaffirmed an “outperform” rating and issued a $40.00 price target on shares of Genocea Biosciences in a research note on Tuesday, July 25th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $18.00 target price (up previously from $17.00) on shares of Genocea Biosciences in a research report on Tuesday, July 25th. Needham & Company LLC upgraded Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research report on Monday, July 24th. Finally, Zacks Investment Research cut Genocea Biosciences from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $16.52.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
